Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Labcorp launches rapid fentanyl test with 48-hour detection window
(57m)
Terremoto takes $108M series C to fuel clinical trials of AKT1 inhibitors
(3h)
FDA official confirms plausible mechanism principles not exclusive to bespoke gene therapies
(10h)
Bain-backed Beeline Medicines buzzes out of stealth with $300M and 5 programs from BMS
(15h)
Cell therapy biotech Obsidian leverages Galera reverse merger to go public
(22h)
Click Therapeutics cuts staff after commercial deal restructuring
(22h)
Astellas to close stem cell unit’s Seattle site, with layoffs incoming
(22h)
Takeda terminates mRNA research pact with Japanese drug discovery specialist
(23h)
Novo taps OpenAI to deploy AI across R&D, manufacturing and corporate functions
(23h)
Australia’s Kazia pays research institute $1.4M for epigenetic platform, preclinical drug
(23h)
BioPharma Dive
Travere wins long-awaited approval for kidney disease drug
(20h)
J&J leans on Tremfya, cancer drugs to overcome Stelara losses
(21h)
Lilly boosts ADC portfolio with CrossBridge Bio deal
(22h)
Novo teams with OpenAI; Ideaya gets muted response to eye drug data
(1d)
Spyre drug for inflammatory bowel disease shows promise in early study
(1d)
Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma
(1d)
Revolution pancreatic cancer drug nearly doubles survival in key trial
(1d)
Connected medical devices: Smarter care starts here
(2d)
Rethinking dermatology trial design for late-stage success
(2d)
FDA again spurns Replimune melanoma drug
(4d)
Endpoints News
Terremoto raises $108M to make an 'earthquake' in small molecule space
(1h)
Beeline Medicines emerges as Bristol Myers' partner for shelved immunology drugs
(2h)
FDA asks for more data on Lilly’s Foundayo to assess heart, liver risks
(19h)
Replimune looks ahead as repeat CRL speeds the company's decline
(19h)
Revolution Medicines leads latest wave of stock offerings, totaling $1.5B
(21h)
Endpoints biopharma sentiment survey for Q2 2026
(22h)
Harbinger raises $100M; Astellas to close Seattle site
(22h)
J&J increasingly confident it can manage Stelara cliff, but work remains
(22h)
Eli Lilly to pay up to $300M for cancer biotech CrossBridge Bio
(1d)
Parker Institute doubles down on cancer vaccines as part of ongoing reboot
(1d)
BioSpace
Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In Silico
(1h)
Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data
(1h)
J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer
(2h)
Could biotech layoffs push life sciences talent to go global?
(6h)
5 biopharma M&A deals where the workforce was the prize
(8h)
Deep dive: Checking in with the FDA
(8h)
FDA bolsters bespoke therapy framework with new draft safety guidelines
(18h)
50 employees impacted as Astellas closes Universal Cells' Seattle office
(21h)
Bonus: Q1 2026 Job Market Update
(22h)
With nearly a quarter billion in Q1, J&J targets $100B revenue in 2026
(22h)
STAT News
Trump DOJ report says Biden administration treated anti-abortion protestors unfairly
(1h)
New Bain biotech startup, building on BMS drugs, gets a name and a CEO
(2h)
AI could check millions of CT scans for heart risk. Who will pay for it?
(4h)
Hosting the ‘intellectual wrestling match’ between MAHA, public health
(4h)
Flawed study on the antidepressant Paxil came with a cautionary note — if you knew how to find it
(4h)
Medical schools must continue to teach students about structural barriers to care
(4h)
Congress returns to a packed health care agenda
(20h)
FDA pressures drugmakers to report trial results
(22h)
Hospitals offer chatbots to fight off ChatGPT
(23h)
We’re reading about an FDA push for trial transparency, a Novo-OpenAI deal, and more
(23h)
BioPharma Trend
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(21h)
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(5d)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(5d)
Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People
(1w)
Epia Neuro Wants to Decode Brain's Movement Intentions After Stroke
(2w)
Generare Raises €20M to Explore Uncharacterized Chemical Space from Microbial DNA
(2w)
Enveda’s AI-Discovered Drug Shows Early Atopic Dermatitis Relief
(2w)
Lilly Signs $2.75B AI Drug Discovery Deal With Insilico
(2w)
Meta Open Sources Foundation Model That Predicts Brain Responses to Speech, Video, and Text
(3w)
Two Ex-GSK AI Leads Go Stealth with a New Oncology Drug Discovery Startup
(3w)
Drug Channels
Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update
(1d)
Informa Connect’s Life Sciences Pricing & Contracting USA
(2d)
The Net Pricing Revolution in the Drug Channel: What’s Deflating the Gross-to-Net Bubble (rerun)
(5d)
The FTC Blows Up Express Scripts’ PBM Model—and Launches the Net Pricing Drug Channel (rerun)
(6d)
List Price Reductions Will Deflate the Gross-to-Net Bubble–and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)
(1w)
Drug Channels News Roundup, Mid-April 2026: Vertical Integration & MLR Games, Copay Maximizers, Hospital Price Chaos, and One Big Drug Channel Family
(1w)
The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs (rerun)
(1w)
Building What’s Next: Join Industry Leaders to Shape Access and Affordability Trends Ahead of Asembia AXS26
(2w)
Drug Channels News Roundup, March 2026: Cigna’s 340B Workaround, Merck’s ARPA Surprise, Walgreens’ Automation Bet, Why Rebates Hurt Patients, and a DCI Team Photo
(2w)
The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments
(2w)
European Biotechnology Magazine
Novo Nordisk is going all in on AI
(3h)
Can Europe finance and keep its biotech winners?
(4h)
Europe’s distinct biotech venture studio model
(4h)
Adcendo banks US$75m to push ADC pipeline forward
(6h)
Clean Food Group to scale yeast-based oils with £4.5m in the bank
(1d)
BioNTech reports promising Phase II data for uterine cancer ADC
(3d)
Basilea lands US$6m CARB X boost for novel antibiotic
(6d)
SLAS Announces the Cohort for Innovation AveNEW at SLAS Europe 2026
(1w)
Jeito Capital raises record US$1.2bn to bankroll European biopharma’s next generation
(1w)
Gilead acquires German ADC specialist Tubulis in US$5bn deal
(1w)
Drug Hunter
BHV-2100
(21h)
orforglipron
(2d)
Module 3 Quiz
(2d)
Daraxonrasib (RMC-6236): The 2025 Molecule of the Year
(5d)
relacorilant (CORT125134)
(6d)
More Firepower Per Molecule: Bispecific and Dual-payload ADCs Push for Greater Efficacy
(7d)
TNO155
(1w)
Module 3, Section 2: Quality not Quantity
(1w)
quemliclustat
(1w)
soquelitinib
(2w)
Labiotech.EU
Mending university and venture capital relations: is it possible to see eye-to-eye?
(4h)
Can phage therapy answer the booming antibiotic resistance problem?
(1d)
Amgen pipeline’s next growth cycle: replacing its old blockbusters
(2d)
Top biotech deals in March 2026
(5d)
Multi-agent AI delivers reliable and scalable insights for single-cell omics
(5d)
Extracellular vesicles: a growing pipeline still searching for validation
(1w)
The biggest biotech funding rounds in March 2026
(1w)
The future of cell & gene therapy: Key trends to watch
(1w)
Nionyx Bio’s kidney gene therapy wins the 2026 BIO-Europe Spring Startup Spotlight
(2w)
Portugal: will the life science sector see upswing amid funding worries?
(2w)
Bio IT World
PARTAGE Method Reveals Genome Regulation in Single Approach
(1d)
CAS Releases Agentic Tool for Literature Discovery
(5d)
'Mini-brain' Model Explores Concussion's Effects at Cellular Level
(6d)
‘Humble’ AI Reveals When It is Uncertain in Diagnoses
(1w)
Inductive Bio on a Winning Streak With ADMET Predictions
(2w)
From Data to Discovery: Inside the Bio-IT Hackathon
(2w)
Mapping the Trillion-Gene Universe: The Startup That Wants to Teach AI the Language of Life
(2w)
The Value of Prediction, and Cost of Success, in Drug Hunting
(3w)
Follow the Money: Brain-Computer Retinal Implant, Expansion of Alzheimer’s Platform, Migraine Therapies
(3w)
Verily, Samsung Collaborate, Improving AI Trustworthiness, FDA Approval for PathAI
(3w)
GEN News
Engineered Miniature CRISPR Boosts Gene‑Editing Efficiency in Human Cells
(13h)
CAR T Cell Therapy Biomanufactured by Cellares Infused Into First Two Patients
(16h)
Regeneron, Telix Launch Up-to-$4.3B Cancer-Focused Radiopharma Drug, Diagnostic Collaboration
(17h)
GLP-1 Drug Improves Liver Health Independent of Weight Loss, Mouse Study Finds
(18h)
AWS Launches Amazon Bio Discovery Agentic AI to Accelerate Drug Development
(22h)
From Colossal to Chickens: The Scientists Behind Neion Bio’s Biologics Platform
(23h)
Sex-Related Differences in Immune System Aging May Impact Disease Susceptibility
(1d)
Salk to Lead $41.3M ARPA-H Effort to Advance Sonogenetics Therapies
(1d)
AACR 2026: Professional Awards Acknowledge Community’s Contributions to Cancer Research
(1d)
Advancing Fully Walkaway Automation in Genomics Workflows
(1d)
Cure Today
Treating Metastatic TNBC: Dr. Hope Rugo on ADCs and Personalized Therapy
(3w)
Understanding High-Risk Essential Thrombocythemia
(3w)
Son’s Decision to Donate Gave His Father a Second Chance
(4w)
Functional Precision Medicine Advances Brain Tumor Care
(4w)
Home-Based Chemotherapy at Mayo Clinic Shows Safe Option for Patients With Cancer
(4w)
Choosing Motherhood Amidst Stage 4 Breast Cancer
(4w)
FDA Approves Opdivo Combo for Newly Diagnosed Advanced Hodgkin Lymphoma
(4w)
How Honest Conversations Strengthened a Couple After Cancer
(4w)
Cardiac Health in Cancer Survivors: A Growing Need
(4w)
Why Open Communication is Crucial for Patients With Multiple Myeloma
(4w)
Contract Pharma
Evotec Names Chief Operating Officer
(9m)
FDA Approves Travere’s Filspari for Treatment of Focal Segmental Glomerulosclerosis
(16h)
Labcorp Unites With AWS and Datavant on AI Platform to Accelerate Alzheimer’s Research
(18h)
BostonGene, ImmunoGenesis Partner to Accelerate Development of Immune Checkpoint Inhibitor
(20h)
Parabilis Medicines Updates Executive Leadership Team
(21h)
Vasa Therapeutics to Use Eli Lilly AI Platform in Drug Discovery Collaboration
(21h)
Valo Health Taps Dr. Chris Anagnostopoulos as Chief Causal AI Officer
(22h)
Kincell Bio Expands Research Triangle Park, North Carolina Facility
(23h)
CS Analytical Appoints Jennifer Roark as Director of Scientific Affairs
(23h)
Vetter Expands Global Clinical Manufacturing Network in U.S. and Europe
(23h)
Pharma Times
Transgene completes randomisation in phase 2 trial of tg4050
(2d)
Bayer wins MHRA approval for Kerendia in heart failure
(2d)
Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
(6d)
Kainova expands DT 7012 trial into Europe
(6d)
Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
(1w)
CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
(1w)
FDA approves new high dose Spinraza regimen for SMA
(2w)
Viridian reports positive results from elegrobart phase 3 trial
(2w)
Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
(2w)
Kygevvi approved in Europe as first treatment for TK2d
(2w)
Medcity News
Heartflow Sues Cardiac AI Rival Cleerly Over Alleged IP Theft
(12h)
Vida Health Teams Up with ŌURA to Provide More Personalized Metabolic Care
(14h)
Bouncing Back From Trial Failure, Travere Wins First FDA Approval in Rare Kidney Disease
(14h)
5 of the Top 10 U.S. Health Systems Are Moving to This New Health IT Category. Here’s Why.
(19h)
Why Synthetic Data is the Antidote to Clinical Trials
(23h)
Clinical Supply Chain Hits Its AI Turning Point
(23h)
Hospital Margins Squeeze as Costs Outpace Revenue Growth
(1d)
Report: Growth in MA Is Associated With Lower Total Medicare Spending
(1d)
Revolution Medicines Reports ‘Unprecedented’ Survival in Pivotal Pancreatic Cancer Trial
(1d)
The AI Value Gap and Why Validation is a Practical First Win for Life Sciences
(2d)
Chemical & Engineering News
Eric Jacobsen named 2026 F. A. Cotton Medal winner
(1h)
Carter to become next CEO of Dow
(17h)
Business Watch: Borouge International emerges; Regeneron, Telix link for radiopharma
(19h)
Satellite data reveal rising methane levels
(19h)
Academic freedom declines in US and 49 other countries, survey finds
(20h)
Memory Lane: From the steering committee to global researcher, professor, and mentor
(20h)
Mouse neurobehaviorist by day; research integrity watchdog by night
(1d)
Simple bath readies lithium-metal anodes for long-range EVs
(1d)
Smita Mohanty named 2026 Oklahoma Chemist of the Year
(1d)
Chemistry in Pictures: Everything that a cell is
(2d)
The Pharma Letter
FDA demands trial safety data on Foundayo after approval
(1h)
Rubicon enters Indian CNS formulations market with buy of Arinna Lifesciences
(1h)
Obsidian and Galera reveal reverse merger plan
(2h)
OSE Immunotherapeutics evolves leadership team
(3h)
Neomorph secures $100M Series B to scale molecular glue degrader pipeline
(5h)
US govt investments in Gilead’s lenacapavir for HIV prevention
(5h)
CrossBridge Bio latest ADC firm to be snapped up in Lilly deal
(20h)
FDA draft guidance on genome editing safety standards
(22h)
Positive Phase III results for Jaypirca in new CLL group
(23h)
Positive Phase III results for Jaypirca in new CLL group
(23h)
Targeted Oncology
Ozekibart Plus Chemo Shows Promising Activity in R/R Ewing Sarcoma
(4w)
Reduced CRS Rates Support Wider Adoption of Bispecifics in Myeloma
(4w)
GLSI-100 Vaccine Shows <1% Annual Recurrence Rate in Phase 3 Breast Cancer Trial
(4w)
Treating Triple Negative Breast Cancer in the Frontline Setting
(4w)
Early Phase Evaluation of Intravesical Erdafitinib in NMIBC
(4w)
Zovegalisib Plus Fulvestrant Shows Durable PFS in PI3Kα-Mutated HR+/HER2− Metastatic Breast Cancer
(4w)
Phase 3 Trial of Eftilagimod Alfa in First-Line NSCLC Halted After Futility Analysis
(4w)
Keeping Bone Health Top of Mind in Androgen Deprivation Therapy
(4w)
Introducing CELMoDs into the Multiple Myeloma Treatment Paradigm
(4w)
Role of Dual Maintenance Remains Uncertain in Multiple Myeloma
(4w)
MedWatch
FDA to review Leo Pharma's hand eczema treatment for youths
(29m)
Industry warns of uncertainty surrounding new EU market protection
(58m)
Long waiting lists and geopolitical headwinds could pose a challenge to Hemab’s IPO plans
(1h)
ALK wins approval for nasal spray in Canada
(1h)
Media: FDA is close to appointing a new head of vaccines and biologics
(2h)
FDA requests additional safety data for Eli Lilly weight-loss pill
(4h)
Kailera and Alamar aim for billion-dollar valuations in new IPOs
(4h)
Zealand Pharma appoints US-based investor relations head
(5h)
Amazon launches AI tool for drug development
(5h)
Gubra scraps development of hyped sleep aid: Professor cites cost
(5h)
In The Pipeline
Answers and Reasons and Knowing and Thinking
(16h)
Predicting Antibody Binding: No Champagne Just Yet
(1d)
Consider the Selfish Ribosome
(5d)
New Bond Formations Just Keep On Coming
(6d)
Ah, Peptides. Where to Begin?
(1w)
A New Opioid Agonist?
(2w)
Say "Chameleonicity" Three Times Fast. Or Read This Post.
(2w)
Right Through the Skull
(2w)
Revving Up LNP Delivery
(2w)
The Latest CAR-T Work
(3w)
Pharmaphorum
Daiichi exits OTC, with $1.55bn unit sale to Suntory
(14m)
Parkinson's charity partners Biognosys on biomarker project
(1h)
Amazon launches its AI drug discovery platform
(2h)
FDA seeks safety data for Lilly's oral GLP-1 Foundayo
(3h)
FDA renews criticism of trial sponsors over transparency
(1d)
Novo Nordisk partners OpenAI on R&D "transformation"
(1d)
Travere claims first FDA OK in rare kidney disease FSGS
(1d)
Revolution rockets on strong pancreatic cancer data
(1d)
Alamar, Hemab, Kailera, and Seaport advance IPOs
(1d)
IDEAYA/Servier PKC drug aces uveal melanoma trial
(2d)
Drug Discovery Weekly
Construction completed on new UK life science facility
(1h)
Access to hyperkalaemia drug expands across England and Wales
(3h)
Immunopeptide could delay inflammatory arthritis, study says
(4h)
Antibody discovery company opens cryo-EM facility in San Diego
(5h)
Laigo Bio announces new CSO as part of board appointments
(20h)
eBook: The Full Guide to Precision Medicine
(23h)
DDW Highlights: 14 April 2026
(1d)
Combo treatment new SOC in platinum-resistant ovarian cancer
(1d)
B7-H4-targeted ADC shows 62% response rate in ovarian cancer
(1d)
NEJM data support Takeda’s treatment for ITP
(1d)
HIT Consultant
The Clinical Resolution Gap: Why AI Can’t Fix Broken MSK Care Platforms
(5h)
Wavelet Medical Secures $7M to Scale AI Fetal Brain Monitoring Globally with Aegis Ventures
(21h)
Finding the Right Five Percent: How Machine Learning Is Reshaping Care Management
(1d)
Ultralight Raises $9.3M to Launch AI-Native Operating System for Healthcare
(1d)
The AI Arms Race: Why PHTI Warns Healthcare ‘Bot Wars’ Are Inflating Medical Costs
(1d)
ModMed Expands Multi-Year Cloud Agreement with AWS to Scale Healthcare AI Solutions
(2d)
symplr Appoints Former Edifecs Executive Venkat Kavarthapu as CEO
(2d)
The Push for Side-by-Side Prescription Pricing in EHR Workflows
(2d)
Death by a Thousand Vendors: Solera Report Reveals The Hidden Costs of Digital Health
(4d)
Qventus Report: 94% of Healthcare CIOs Say AI Delays Create Competitive Disadvantage
(4d)
Insights: Pink Sheet
Prolonged Iran Ports Blockade Risks Drug Shortages, Wider Supply Chain Woes
(8h)
US FDA To Clarify Plausible Mechanism Framework With Genome Editing Guidances, Workshop
(15h)
US FDA’s Literature-Based Leucovorin Approval May Offer A Rare Disease Template
(16h)
Does FDA Untitled Letter For Adcetris Facebook Ads Signal Start Of Social Media Crackdown?
(19h)
US Tariffs To Hit European Pharmaceutical SMEs Disproportionately
(23h)
EMA Aligns With US On Severe Liver Injury Warning For Angelini’s Ontozry
(1d)
New CBER Director Candidate Could Signal Industry Cred Important Again
(1d)
US FDA Wants Sponsors to Offer Real Plans For Pediatric Cell/Gene Therapy Trials
(1d)
More Tariff Uncertainty For Chinese Companies with US FDA-Approved Drugs
(1d)
US FDA’s CDER, CBER Continue Hiring Staff, But More Continue To Leave
(1d)
BioXconomy
Beyond Redaction: Governing Confidential Information in an Era of Expaning Transparency
(1d)
FDA proposes faster Phase I trial approvals to boost US competitiveness
(9h)
Eli Lilly bets $300m on CrossBridge Bio's dual-payload ADC platform
(18m)
FDA stability and gene therapy payment models discussed
(32m)
Biogen’s blueprint for collaboration in China’s thriving pharma landscape
(4h)
Thermo Fisher expands RWD with HealthVerity deal
(17h)
Regeneron and Telix ink $2.1bn partnership to advance radiopharma therapies
(21h)
Fortrea debuts AI trial tech to enhance drug RD
(22h)
mRNA technology brims with possibility across a range of diseases
(1d)
Eyes on Asia: Takeda, Insilico, Oricell
(1d)
BioCentury
Remembering Sofinnova’s Denis Lucquin, father of French biotech
(11h)
Novartis’ Narasimhan joins Anthropic board
(12h)
Zentalis leads movers in trio of ovarian cancer updates
(13h)
Psoriasis paves the way for next-generation TYK2 inhibitors in autoimmunity
(15h)
FDA’s FIH plans. Plus: billion-dollar deals, funds — a BioCentury podcast
(1d)
RevMed’s pancreatic cancer win strengthens the case for targeting RAS(ON)
(1d)
Biotech executive, combative conservative Hemmati may head CBER
(1d)
IPO queue grows as Seaport, Hemab line up NASDAQ offerings
(1d)
Regeneron enters radiotherapy, Gilead buys another biotech, and more: Deals Report
(1d)
Fibrosis company Avalyn seeks NASDAQ listing amid volatility: Finance Report
(4d)
SCRIP
BMS/Bain $300m Venture Emerges As Beeline With Lead Asset Nearing Pivotal Stage
(1h)
Daiichi Sankyo Tightens Oncology Focus Through OTC Divestment To Suntory
(3h)
Alphamab’s Bispecific Phase III Win In Breast Cancer Lays Runway For Take Off
(4h)
AZ Optimistic On Japan Prospects Despite Pricing, LoE Challenges
(7h)
Great Expectations: Icotyde Could Be J&J’s Biggest Product Ever, Duato Says
(16h)
Obsidian Will Go Public Via Merger With Galera And Raise $350m
(16h)
Eli Lilly To Buy CrossBridge And Its Dual-Payload ADC Tech
(17h)
Evommune Makes Case For MRGPRX2 Inhibition in Migraine
(21h)
The 2026 Scrip Awards Is Open For Entries
(1d)
Travere’s Filspari Is First Drug Approved For FSGS
(1d)